retatrutide clinical trials phase 2 Availability & Timeline retatrutide dosing phase 2 trial

Lipolytic and Insulinotropic Effects of HM12525A, A Novel Long-Acting GLP-1/Glucagon Dual Agonist

BPC-157 came off the FDA Category 2 list effective April 23, 2026, and is one of the seven peptides under PCAC review for 503A compounding eligibility in July 2026

Thymalin Epithalon Peptide Stack Research Applications Preclinical studies involving thymalin epithalon peptide stack have explored the following areas: Telomere biology Studies have examined the relationship between this compound and telomere length maintenance in ageing cell models

In addition, only one of 15 cells (6.7%) was depolarized by 2.7 mV in response to Ex-4c (green dots in Fig

Eli Lilly: The Battle for Anti-Obesity Drug Market Dominance Table of Contents The global obesity crisis has sparked a multibillion-dollar showdown in the pharmaceutical world, with Novo Nordisk and Eli Lilly locked in an intense battle for supremacy